Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2025 Annual Report please use our contact form or send an email to ir@qiagen.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.

Source: QIAGEN N.V.

Category: Corporate

Contacts

Investor Relations
e-mail: ir@QIAGEN.com

Public Relations
e-mail: pr@QIAGEN.com

Industry:

QIAGEN N.V.

FWB:QIA

Details

Headquarters: Venlo, Netherlands

Website: www.qiagen.com

CEO: Thierry Bernard

Employees: 5800

Organization: PUB

Revenues: US$ 1.97 billion (2023)

Net Income: US$ 341.3 million (2023)

Release Versions

$Cashtags

Hashtags

#moleculardiagnostics

#sampletechnologies

#science

#syndromictesting

Contacts

Investor Relations
e-mail: ir@QIAGEN.com

Public Relations
e-mail: pr@QIAGEN.com

Social Media Profiles

More News From QIAGEN N.V.

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is availa...

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability. Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at constant exchange rates (CER) compared to Q2 2025, exceeding the outlook for an approximately 2% CER decline. QIAGEN’s growth pillars together delivered 5% CER gro...

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States. More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis,...

Back to Newsroom